Allakos, which is developing antibodies for allergic, inflammatory and proliferative diseases, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
Its lead program has received orphan drug designation in the US for eosinophilic gastritis and eosinophilic gastroenteritis.
The San Carlos, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol ALLK. Goldman Sachs and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
